Rheumatoid Arthritis

Shedding Weight and Pain: The Promise of Anti-Obesity Medications in RA For years, rheumatologists have championed weight loss as a cornerstone of care for patients with rheumatoid arthritis (RA) and obesity. RA is an independent risk factor for cardiovascular disease (CVD), a… https://t.co/iozo0FQFzj https://t.co/93e4nZMHJo
Dr. John Cush @RheumNow( View Tweet )
RheumNow Day 2 Recap: #ACR24 Highlights Catch the latest insights from the ACR Annual Meeting, where leading experts share groundbreaking research and clinical advances in rheumatology. Don’t miss our live coverage of key takeaways and trends shaping the future of patient care.… https://t.co/F3rZzOTiSJ https://t.co/t3wROMBe7D
Dr. John Cush @RheumNow( View Tweet )

RA: One JAK to Rule Them All? Dr. Brian Jaros reports on abstract 1362, presented at #ACR24. https://t.co/QChMyma3Y2 https://t.co/qq3BqpT2Gh

Links:

Dr. John Cush @RheumNow( View Tweet )
Sleep asleep

Dreaming of Relief: The Importance of Sleep in Lupus and Rheumatoid Arthritis

Andrea Fava, MD

Sleep plays a critical role in regulating inflammation and overall health. In rheumatic diseases like lupus and rheumatoid arthritis (RA), disrupted sleep is common and can exacerbate symptoms and disease progression. Experts Dr. Al Kim, Patty Katz, and Dr. Yvonne Lee emphasized the importance

Read Article
maze-1804499_1280.jpg

Methotrexate to Prevent RA, Clear as Mud

Richard Conway, MBBChBAO, PhD

Intervention in individuals predisposed to develop RA, with a holy grail of prevention of RA, has long been a hot topic. The 4-year results of the TREAT EARLIER study, presented at Tuesday’s oral abstract session, show that methotrexate appears to prevent the development of RA in high risk

Read Article
artificial intelligence machine learning computer

Predicting flares in rheumatic diseases with machine learning

Antoni Chan, MD, PhD

Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes. Advances in machine learning (ML) provide a promising avenue for predicting these

Read Article
Prgnancy,outcome

Improving fertility in women with RA

Jiha Lee, MD

For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way

Read Article
Finding the Right Combination Therapy in RA Dr. Jonathan Kay interviews Dr. Ernest Choy about abstract 0521, Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in RA, presented at… https://t.co/yPmDIZ6aKI https://t.co/cairKrbDDu
Dr. John Cush @RheumNow( View Tweet )
RheumNow Day 4 Recap: ACR Convergence 2024 Highlights https://t.co/WvQB7y0bkm

Links:

Dr. John Cush @RheumNow( View Tweet )

Are we under-monitoring in scleroderma ILD? Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of… https://t.co/1y1VXGvqjp https://t.co/4ofh45cYwq
Dr. John Cush @RheumNow( View Tweet )
Lacaille et al. Long term harms of previous steroids in RA. CV/infection mortality increase 7% every year/use. Takes 3.5 and 10 years to return to normal after 1 and 2 years use. Never returns to normal if >2 years use @RheumNow #ACR24 Abstr#2673 #ACRbest https://t.co/qcp5mCHmeB https://t.co/keXw5Qg2ld

Links:

Richard Conway @RichardPAConway( View Tweet )
Does CVD mortality risk change after stopping GC in RA? ➡️28078 incident GC users ➡️Incr mortality risk from CVD &infections persists post-cessation ➡️Risk never returns to pre-GC level after prolonged use ⏩Use GC at lowest dose for shortest time possible Ab2673 #ACR24 @Rheumnow https://t.co/dtLU8obLke

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
Ab2674 #ACR24 ➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12 ➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M @RheumNow https://t.co/pFOo86tJTx

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
An early favorable response to TNFi initiation indicates better long-term success in RA. Assess early and adjust treatment accordingly. #ACR24 @RheumNow ABST#2674 https://t.co/YTThYiiLpZ

Links:

Jiha Lee @JihaRheum( View Tweet )
#ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ

Links:

Dr. John Cush @RheumNow( View Tweet )
Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx

Links:

Janet Pope @Janetbirdope( View Tweet )
In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or Ab levels in Anifrolumab-treated pts. AEs - mild, moderate No serious aEs 💉#vaccinate your pts on anifrolumab with influenza @RheumNow #ACR24 abs2424 https://t.co/XPwlzUS02i

Links:

sheila @RHEUMarampa( View Tweet )
Mortality Risk After Stopping Glucocorticosteroids (GC) in RA. In a study of 28,078 RA patients: Mortality risk from CVD ↑ 7.5%/year of GC use; ↓ 1.3%/year after stopping. Mortality risk from infections ↑ 6.8%/year of GC use; ↓ 4.9%/year after stopping. Risks normalize 1.5–10… https://t.co/i6cKet1EEV https://t.co/ClMjIly20E

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#Poorer responses to #Rx in #Females vs #males Sex hormone and pathway differences explained 👇 Biological differences F start worse in disease activity F May have ⬇️ response to #Rx Yr in Preview C Ritchlin @lihi_eder’s PsA work quoted ACR24 @RheumNow @ACRheum @ACRBest https://t.co/EWoCvzOLiL

Links:

Janet Pope @Janetbirdope( View Tweet )
VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA. RA patients vaccinated with PCV13 1 month before MTX initiation had higher responder rates at 1 month: 88% (ELISA) vs. 75% 96% (OPA) vs. 88% At 12 months, responses remained stronger in… https://t.co/bSbIazsRtG

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )

Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr

Links:

Richard Conway @RichardPAConway( View Tweet )
Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs

Links:

Richard Conway @RichardPAConway( View Tweet )
In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II #ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe

Links:

Jiha Lee @JihaRheum( View Tweet )
Yes No

Playing it Safe with RA? JAK vs. TNF Debate

Brian Jaros, MD

Reported safety signals, at odds with the efficacy of these medications, have left rheumatology clinicians in a difficult position when considering when during a patient’s treatment course and in which patients, specifically, JAKi should be used. Two abstracts from ACR convergence 2024 further

Read Article
Is Pregnancy Truly the Solution for RA? Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or… https://t.co/MesVIUl0fC https://t.co/760i5znmeu
Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

Best of 2023: New ACR RA-ILD Treatment Guidelines – What Were They Smoking!?

Richard Conway, MBBChBAO, PhD
Lungs ILD
Rheumatoid arthritis related interstitial lung disease (RA-ILD) is common, with symptomatic RA-ILD affecting approximately 8% of RA patients. There is a very limited evidence base supporting treatment and therefore the recent release of ACR guidelines is to be welcomed. However, the published guidelines appear discordant with the best available evidence base.  Read Post

Screening and Overdiagnosis of ILD in RA

Michael Putman, MD, MSCI
Putman RheumThoughts
Dr. Michael Putman (Milwaukee, WI) reviews his approach to screening for ILD and RA, the potential for overdiagnosis and how this impacts treatment choices. Does this differ from your approach? Read Post

Featured Video

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.